Association of American Cancer Institutes to Recognize NCI Acting Director for Scientific Achievements


  • newswise-fullscreen Association of American Cancer Institutes to Recognize NCI Acting Director for Scientific
Achievements

    Douglas R. Lowy, MD, acting director of the National Cancer Institute.

Newswise — Douglas R. Lowy, MD, acting director of the National Cancer Institute (NCI), will receive the

AACI Distinguished Scientist Award on October 21, during the 2019 AACI/CCAF Annual Meeting

in Washington, DC.

The Association of American Cancer Institutes (AACI) is recognizing Dr. Lowy for his long-term

research on the molecular biology of tumor viruses and growth regulation, his role in enabling

the development of human papillomavirus (HPV) vaccines, and his exploration of oncogenes

and tumor suppressor genes and their signaling pathways.

“The AACI board and national membership is honored to have this opportunity to recognize Dr.

Lowy’s scientific achievements,” said AACI President Roy A. Jensen, MD. “Doug has been a

champion of AACI cancer centers throughout his tenure at the NCI, and his breakthrough

laboratory discoveries have been an invaluable resource for the cancer research community.”

Dr. Lowy was named NCI’s acting director in April 2019 following the appointment of then-NCI

Director Norman Sharpless, MD, as acting commissioner of the U.S. Food and Drug

Administration. Dr. Lowy also served as acting director from April 2015 to October 2017. Prior

to these appointments, Dr. Lowy had held the NCI deputy director position since 2010, helping

to lead NCI’s key scientific initiatives.

Dr. Lowy’s current research is examining the DLC1 tumor suppressor, which encodes a Rho-GAP

that is down-regulated in a wide variety of cancers, leading to the high Rho activity seen in

many advanced cancers. This work has identified important scaffold functions for DLC1,

including protein-protein interactions that contribute to the regulation of its activity and its role

as a tumor suppressor, and identified kinases that activate and inactivate the functions of DLC1

and the mechanisms by which they do so. Dr. Lowy also continues to pursue research on HPV.

In addition to serving as NCI acting director, Dr. Lowy is chief of the Laboratory of Cellular

Oncology in NCI’s Center for Cancer Research. In 2014, Dr. Lowy, with his colleague John

Schiller, MD, were honored by President Obama with the National Medal of Technology and

Innovation. In 2017, the scientists received the Lasker-DeBakey Clinical Medical Research

Award, the country’s most prestigious honor for biomedical research, for their significant

research leading to the development of HPV vaccines. They were also recognized for their

contributions toward the development of HPV vaccines with the 2018 Szent-Györgyi Prize for

Progress in Cancer Research.

“At a time when AACI members are striving to eliminate cervical cancer and other HPV-related

cancers, Dr. Lowy’s contributions to science are especially significant,” said AACI Executive

Director Jennifer W. Pegher. “AACI is proud to honor Dr. Lowy for his positive impact on cancer

research and prevention.”

Previous AACI distinguished scientist honorees are Drs. Charles Perou, Carl June, James Allison,

Lewis Cantley, Tim Ley, Brian Druker, Lee Hartwell, Mary-Claire King, Janet Rowley, Stuart

Schreiber, Bert Vogelstein, Robert Weinberg, and Irving Weissman.

###

Representing 98 of North America's premier academic and freestanding cancer centers, the Association

of American Cancer Institutes is dedicated to reducing the burden of cancer by enhancing the impact of

leading cancer centers.

  • share-facebook-Association of American Cancer Institutes to Recognize NCI Acting Director for Scientific
Achievements
  • share-twitter-Association of American Cancer Institutes to Recognize NCI Acting Director for Scientific
Achievements

Comment/Share

Chat now!